BACKGROUND: Deletion of Toll-like receptor 9 (Tlr9) signaling, which is important for sterile inflammatory processes, results in impaired resolution of venous thrombosis (VT) in mice. The purpose of this study was to determine if deletion of Tlr9 affected sterile necrosis, apoptosis, and neutrophil extracellular trap (NET) production in VT. METHODS: Stasis and nonstasis murine models of VT were used in wild-type (WT) and Tlr9-/- mice, with assessment of thrombus size and determination of NETs, necrosis, and apoptosis markers. Anti-polymorphonuclear neutrophil (PMN) and antiplatelet antibody strategies were used to determine the cellular roles and their roles in WT and Tlr9-/- mice. RESULTS: At 2 days, stasis thrombi in Tlr9-/- mice were 62% larger (n = 6-10), with 1.4-fold increased uric acid levels, 1.7-fold more apoptotic cells, 2-fold increased citrullinated histones, 2-fold increased peptidylarginine deiminase 4 (PAD4), and 1.5-fold increased elastase and a 2.4-fold reduction in tissue factor pathway inhibitor compared with WT mice (all n = 4-7; P < .05). In contrast, the sizes of nonstasis thrombi were not significantly different in Tlr9-/- mice (n = 4-6), and they did not have elevated necrosis or NET markers. Stasis thrombus size was not reduced at the 2-day time point in WT or Tlr9-/- mice that received treatment with deoxyribonuclease I or in PAD4-/- mice, which are incapable of forming NETs. In Tlr9-/- mice undergoing PMN depletion (n = 8-10), stasis thrombus size was reduced 18% and was associated with 29-fold decreased citrullinated histones, 1.3-fold decreased elastase, and 1.5-fold increased tissue factor pathway inhibitor (all n = 6; P < .05). Last, platelet depletion (>90% reduction) did not significantly reduce stasis thrombus size in Tlr9-/- mice. CONCLUSIONS: These data suggest that the thrombogenic model affects Tlr9 thrombogenic mechanisms and that functional Tlr9 signaling in PMNs, but not in platelets or NETs, is an important mechanism in early stasis experimental venous thrombogenesis.
BACKGROUND: Deletion of Toll-like receptor 9 (Tlr9) signaling, which is important for sterile inflammatory processes, results in impaired resolution of venous thrombosis (VT) in mice. The purpose of this study was to determine if deletion of Tlr9 affected sterile necrosis, apoptosis, and neutrophil extracellular trap (NET) production in VT. METHODS: Stasis and nonstasis murine models of VT were used in wild-type (WT) and Tlr9-/- mice, with assessment of thrombus size and determination of NETs, necrosis, and apoptosis markers. Anti-polymorphonuclear neutrophil (PMN) and antiplatelet antibody strategies were used to determine the cellular roles and their roles in WT and Tlr9-/- mice. RESULTS: At 2 days, stasis thrombi in Tlr9-/- mice were 62% larger (n = 6-10), with 1.4-fold increased uric acid levels, 1.7-fold more apoptotic cells, 2-fold increased citrullinated histones, 2-fold increased peptidylarginine deiminase 4 (PAD4), and 1.5-fold increased elastase and a 2.4-fold reduction in tissue factor pathway inhibitor compared with WT mice (all n = 4-7; P < .05). In contrast, the sizes of nonstasis thrombi were not significantly different in Tlr9-/- mice (n = 4-6), and they did not have elevated necrosis or NET markers. Stasis thrombus size was not reduced at the 2-day time point in WT or Tlr9-/- mice that received treatment with deoxyribonuclease I or in PAD4-/- mice, which are incapable of forming NETs. In Tlr9-/- mice undergoing PMN depletion (n = 8-10), stasis thrombus size was reduced 18% and was associated with 29-fold decreased citrullinated histones, 1.3-fold decreased elastase, and 1.5-fold increased tissue factor pathway inhibitor (all n = 6; P < .05). Last, platelet depletion (>90% reduction) did not significantly reduce stasis thrombus size in Tlr9-/- mice. CONCLUSIONS: These data suggest that the thrombogenic model affects Tlr9 thrombogenic mechanisms and that functional Tlr9 signaling in PMNs, but not in platelets or NETs, is an important mechanism in early stasis experimental venous thrombogenesis.
Authors: Graciela Andonegui; Steven M Kerfoot; Kelly McNagny; Kirsten V J Ebbert; Kamala D Patel; Paul Kubes Journal: Blood Date: 2005-06-16 Impact factor: 22.113
Authors: Jonathan L Eliason; Kevin K Hannawa; Gorav Ailawadi; Indranil Sinha; John W Ford; Michael P Deogracias; Karen J Roelofs; Derek T Woodrum; Terri L Ennis; Peter K Henke; James C Stanley; Robert W Thompson; Gilbert R Upchurch Journal: Circulation Date: 2005-07-12 Impact factor: 29.690
Authors: A Brill; T A Fuchs; A S Savchenko; G M Thomas; K Martinod; S F De Meyer; A A Bhandari; Denisa D Wagner Journal: J Thromb Haemost Date: 2012-01 Impact factor: 5.824
Authors: Peter K Henke; Mayo Mitsuya; Catherine E Luke; Megan A Elfline; Joseph F Baldwin; K Barry Deatrick; Jose A Diaz; Vikram Sood; Gilbert R Upchurch; Thomas W Wakefield; Cory Hogaboam; Steven L Kunkel Journal: Arterioscler Thromb Vasc Biol Date: 2010-10-21 Impact factor: 8.311
Authors: Kristopher B Deatrick; Catherine E Luke; Megan A Elfline; Vikram Sood; Joseph Baldwin; Gilbert R Upchurch; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke Journal: J Vasc Surg Date: 2013-03-13 Impact factor: 4.268
Authors: Soumya Panigrahi; Yi Ma; Li Hong; Detao Gao; Xiaoxia Z West; Robert G Salomon; Tatiana V Byzova; Eugene A Podrez Journal: Circ Res Date: 2012-10-15 Impact factor: 17.367
Authors: Peter K Henke; Andrea Varga; Sumit De; C Barry Deatrick; Jonathon Eliason; Douglas A Arenberg; Pasu Sukheepod; Porama Thanaporn; Steven L Kunkel; Gilbert R Upchurch; Thomas W Wakefield Journal: Arterioscler Thromb Vasc Biol Date: 2004-04-22 Impact factor: 8.311
Authors: Marie-Luise von Brühl; Konstantin Stark; Alexander Steinhart; Sue Chandraratne; Ildiko Konrad; Michael Lorenz; Alexander Khandoga; Anca Tirniceriu; Raffaele Coletti; Maria Köllnberger; Robert A Byrne; Iina Laitinen; Axel Walch; Alexander Brill; Susanne Pfeiler; Davit Manukyan; Siegmund Braun; Philipp Lange; Julia Riegger; Jerry Ware; Annekathrin Eckart; Selgai Haidari; Martina Rudelius; Christian Schulz; Katrin Echtler; Volker Brinkmann; Markus Schwaiger; Klaus T Preissner; Denisa D Wagner; Nigel Mackman; Bernd Engelmann; Steffen Massberg Journal: J Exp Med Date: 2012-03-26 Impact factor: 14.307
Authors: Andrea T Obi; Elizabeth Andraska; Yogendra Kanthi; Chase W Kessinger; Megan Elfline; Cathy Luke; Teruna J Siahaan; Farouc A Jaffer; Thomas W Wakefield; Peter K Henke Journal: Thromb Haemost Date: 2016-12-15 Impact factor: 5.249
Authors: He Meng; Srilakshmi Yalavarthi; Yogendra Kanthi; Levi F Mazza; Megan A Elfline; Catherine E Luke; David J Pinsky; Peter K Henke; Jason S Knight Journal: Arthritis Rheumatol Date: 2017-03 Impact factor: 10.995
Authors: Jeremy S Tilstra; Shinu John; Rachael A Gordon; Claire Leibler; Michael Kashgarian; Sheldon Bastacky; Kevin M Nickerson; Mark J Shlomchik Journal: J Clin Invest Date: 2020-06-01 Impact factor: 14.808
Authors: Ofir Wolach; Rob S Sellar; Kimberly Martinod; Deya Cherpokova; Marie McConkey; Ryan J Chappell; Alexander J Silver; Dylan Adams; Cecilia A Castellano; Rebekka K Schneider; Robert F Padera; Daniel J DeAngelo; Martha Wadleigh; David P Steensma; Ilene Galinsky; Richard M Stone; Giulio Genovese; Steven A McCarroll; Bozenna Iliadou; Christina Hultman; Donna Neuberg; Ann Mullally; Denisa D Wagner; Benjamin L Ebert Journal: Sci Transl Med Date: 2018-04-11 Impact factor: 17.956